Clinical trial · Interventional
In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To date, little is understood regarding post-COVID fatigue or cancer fatigue though it is known to affect a large proportion of patients (10-70% depending on the population). This study aims to investigate potential mitochondrial function and metabolic changes in brain to provide further information regarding the etiology of these changes leading to fatigue. This study hypothesized that Post-COVID fatigue is ensued by perturbations in metabolism and mitochondrial function in the brain. This is a case-control study. In this study, 30 patients (experimental group) complaining of persistent fatigue lasting longer than 4 weeks after recovering from SARS-CoV-2 infection and the age/gender-matched control of 30 healthy subjects (control group 1) and 30 patients suffering from cancer-related fatigue patients longer than 4 weeks after remission (control group 2). Both the experimental group (post-COVID fatigue) and control group 2 (cancer fatigue) will be recruited from NUH outpatient clinic will undergo a session of MRI, 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) and the Chalder Fatigue Scale, Health Questionnaire (EQ-5D-5L) and Hamilton Depression Rating Scale at baseline and follow-up visit.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COVID-19 | — | UNRESOLVED | — |
| Fatigue | — | UNRESOLVED | — |
| Mitochondrial Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chalder Fatigue Scale | Other | — | UNRESOLVED |
| Hamilton Depression Rating Scale | Other | — | UNRESOLVED |
| Health Questionnaire (EQ-5D-5L) | Other | — | UNRESOLVED |
| MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- COVID fatigue patients
- description
- MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
- interventionNames
- Other: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
- Other: Chalder Fatigue Scale
- Other: Health Questionnaire (EQ-5D-5L)
- Other: Hamilton Depression Rating Scale
- type
- ACTIVE_COMPARATOR
- label
- Cancer fatigue patients
- description
- MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
- interventionNames
- Other: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
- Other: Chalder Fatigue Scale
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * age between 21 and 70 years old (all 3 groups) * SARS-COV-2 disease confirmed by PCR or ART (experimental group) * Chalder Fatigue Score (CFQ-11): \>= 19 (experimental group and control group 2), =\< 11 (control group 1) * able to understand the study purpose and consent to it (all 3 groups) Exclusion Criteria: * medically unstable * contraindications for MR scanning (metallic implants, claustrophobia) * requiring oxygen supplementation * unable to follow instructions * anemia (Hb \< 10g/dl) * thyroid disorder * neoplasm (applicable only to experimental group and control group 1) * premorbid sleep disorder * premorbid psychiatric disorders including depression * pregnancy * epilepsy
References
Publications (8)
- BACKGROUNDBlomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, Lartey S, Onyango TB, Kuwelker K, Saevik M, Bartsch H, Tondel C, Kittang BR; Bergen COVID-19 Research Group; Cox RJ, Langeland N. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 Sep;27(9):1607-1613. doi: 10.1038/s41591-021-01433-3. Epub 2021 Jun 23. PMID 34163090
- BACKGROUNDFiller K, Lyon D, Bennett J, McCain N, Elswick R, Lukkahatai N, Saligan LN. Association of Mitochondrial Dysfunction and Fatigue: A Review of the Literature. BBA Clin. 2014 Jun 1;1:12-23. doi: 10.1016/j.bbacli.2014.04.001. PMID 25147756
- BACKGROUNDLogue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021 Feb 1;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830. PMID 33606031
- BACKGROUNDMiller B, Silverstein A, Flores M, Cao K, Kumagai H, Mehta HH, Yen K, Kim SJ, Cohen P. Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples. Sci Rep. 2021 Jan 8;11(1):3. doi: 10.1038/s41598-020-79552-z. PMID 33420163
- BACKGROUNDTomas C, Brown A, Strassheim V, Elson JL, Newton J, Manning P. Correction: Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One. 2018 Feb 8;13(2):e0192817. doi: 10.1371/journal.pone.0192817. eCollection 2018. PMID 29420633
- BACKGROUNDTomas C, Lodge TA, Potter M, Elson JL, Newton JL, Morten KJ. Assessing cellular energy dysfunction in CFS/ME using a commercially available laboratory test. Sci Rep. 2019 Aug 7;9(1):11464. doi: 10.1038/s41598-019-47966-z. PMID 31391529
- BACKGROUNDKantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol. 2003 May;24(5):843-9.